RTS,S/AS01 vaccine (Mosquirix™): an overview

Area of Science:

• Tropical Medicine
• Vaccinology
• Parasitology

Background:

• Malaria, caused by Plasmodium parasites and transmitted by mosquitoes, remains a significant global health threat.
• P. falciparum is the deadliest malaria species, causing substantial human morbidity and mortality.
• While control efforts have reduced malaria cases, progress has stalled, necessitating new interventions.

Purpose of the Study:

• To introduce the RTS,S vaccine as a novel tool to combat malaria.
• To highlight the vaccine's potential impact, particularly in high-transmission regions.
• To provide an overview of the RTS,S vaccine's development and implementation.

Main Methods:

• Development of the RTS,S vaccine initiated in 1987.
• Pilot implementation of the vaccine began in endemic countries in 2019.
• Evaluation of vaccine efficacy against malaria illness.

Main Results:

• The RTS,S vaccine demonstrates modest efficacy in preventing malaria.
• The vaccine shows promise as a public health intervention.
• Efficacy is particularly noted in children residing in high-transmission areas.

Conclusions:

• The RTS,S vaccine represents a timely addition to malaria control strategies.
• It offers a new public health tool, especially for vulnerable populations.
• Continued efforts are needed to combat malaria, with vaccines playing a crucial role.